Introduction {#S1}
============

The last four decades have witnessed tremendous improvement on the survival rates of children suffering from acute lymphoblastic leukemia (ALL), which was made possible, thanks to the prominent effort of various multicenter Cooperative ALL Treatment Groups. Different immunophenotype and genetic subgroups of ALL were identified, which in conjunction with the evaluation of the patient's initial response to therapy, through minimal residual disease (MRD) quantification at different time-points, have allowed the development of tailored treatment protocols by all the Cooperative Groups. Today, in the best contemporary treatment protocols, survival rates for childhood ALL patients are above 85%. Approximately one-third of all deaths are due to treatment toxicity, even with the high-quality supportive care available in high-income countries ([@B1], [@B2]).

However, for children with ALL living in low- and middle-income countries, survival rates are yet significantly lower than those attained in high-income areas of the world ([@B3], [@B4]). Several factors contribute to the inferior survival results, including lower socioeconomic status and education, limited access to specialized centers, reduced offer of genetic, immunophenotyping and molecular biology exams, and shortage of some chemotherapeutic drugs. All these factors are interconnected in a complex way and contribute to failure of adherence to treatment, thus playing an important role in clinical practice.

Maintenance therapy is as important as the more intensive and toxic earlier treatment phases, and often more challenging ([@B5]). Treatment of childhood ALL requires a prolonged maintenance phase that relies on self- or parent-administered daily antimetabolite chemotherapy given over a period of about 2 years ([@B6]--[@B9]). A systematic review of 42 randomized studies with 12,000 childhood ALL cases indicated that longer maintenance therapy gave a slightly lower risk of relapse but with no difference in survival due to a higher risk of death in remission ([@B10]). Lack of adherence, as well as associated infections, are important issues associated to unsuccessful maintenance treatment. We reasoned that a shorter maintenance therapy could be advantageous for the patients and their families, both by favoring adherence and by shortening the immunosuppression period. In the Brazilian Cooperative Group for Childhood ALL Treatment ALL-93 protocol (GBTLI ALL-93), the treatment schema included the induction (phase 1 and 2), consolidation and an intensification phase, followed by 18- or 24-month maintenance therapy.

Objective {#S1-1}
---------

The primary aim of this study was to compare, according to the intention-to-treat, the event-free survival (EFS) rates in children with ALL randomized at diagnosis, to receive a maintenance therapy regimen of 18 vs. 24 months duration.

Materials and Methods {#S2}
=====================

Patients {#S2-1}
--------

Eight hundred and sixty seven consecutive patients with newly diagnosed ALL, aged 0--18 years, who received no previous glucocorticoid treatment, were enrolled in the clinical trial GBTLI ALL-93 between October 1993 and September 1999. Twenty-five Brazilian institutions participated in the study. The diagnosis of ALL was based only on the morphological and cytochemistry features of the leukemic cells from bone marrow specimens. Immunophenotype and genetic features of the leukemic blasts were not required as obliged inclusion criteria, due to the lack of these exams in most Brazilian institutions at that time. Central morphological review was recommended. The protocol was approved by the Ethical Committee (IRB) of each of the 25 participating institutions and written informed consent was obtained for each participant (patients or parents/guardians, as appropriate).

Initial risk classification was based on patient's age and leukocyte count at baseline (National Cancer Institute Risk Group Criteria) and clinical extra medullary involvement of the disease. As previously mentioned, immunophenotyping, ploidy, and cytogenetic were not considered as a risk variable in the study. Patient's biological response was also not considered to define further risk stratification. Very low-risk group (VLR) was defined by age ≥1 and \<10 years, with WBC ≤ 10,000/mm ([@B3]), no mediastinal mass or central nervous system (CNS) involvement, and hepatosplenomegaly \<5 cm below costal margin. Low-Risk Group (LR) was defined by age ≥1 and \<10 years, WBC \> 10,000/mm^3^ and \<50,000/mm^3^, and/or mediastinal mass, and/or hepatosplenomegaly ≥5 cm. High-Risk Group (HR) was defined by age \<1 or ≥10 years, and/or WBC ≥ 50,000/mm^3^, and/or CNS involvement at diagnosis. Complete clinical examination was routinely performed at the time of enrollment into the study.

Only 14 patients were excluded at diagnosis for the following reasons: acute myeloid leukemia (AML) diagnosis in 7 children and previous corticosteroid administration in other 7 patients. Of the 853 eligible patients, 421 were randomly allocated to receive 18 months (group 1) and 432 to receive 24-month (group 2) maintenance therapy. Randomization was performed at study enrollement by a central office. Fifteen children did not follow the randomized group due to medical misunderstanding: 12 from the 18-month group and 3 from the 24-month group. It is important to emphasize that the overall treatment duration refers to the actual therapy received by the patient. Thirty-four patients were lost to follow-up (4.0%), being analyzed only till the abandonment time. For statistical analysis, abandonment was considered as an event.

Treatment Schedule {#S2-2}
------------------

Regimens were proposed according to the initially defined risk groups, as detailed in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Briefly, VLR and LR group patients received *Induction therapy* (6 weeks) with dexamethasone (DEXA) 6 mg/m^2^/day × 28 days, Vincristine (VCR) 1.5 mg/m^2^/week × 4, Daunomycin 25 mg/m^2^/week × 4, [l]{.smallcaps}-Asparaginase 10,000 U/m^2^ IM × 8 and Ara-C 75 mg/m^2^/dose × 8 and triple intrathecal therapy (TIT) with methotrexate (MTX)/Cytarabine (Ara-C)/DEXA (according to age) at days 0, 29, and 43. *Intensification phase* (6 weeks) with MTX 2 g/m^2^ IV 24 h infusion with leucovorin (LCV) rescue 15 mg/m^2^/dose × 4, 6-Mercaptopurine (6-MP) 50 mg/m^2^/day × 6 weeks, and TIT × 4. *Reinduction phase* (6 weeks) with DEXA 6 mg/m^2^/day × 3 weeks, VCR 1.5 mg/m^2^/week × 4, [l]{.smallcaps}-ASP 10,000 U/m^2^ IM × 4, 6-MP 50 mg/m^2^/day × 2 weeks, Ara-C 75 mg/m^2^/day SC × 8 days, and TIT × 3. Patients were centrally randomized to receive *maintenance therapy* during 18 months (group 1) or 24 months (group 2) with 6-MP 50mg/m^2^/day continuously, MTX 25 mg/m^2^/week IM, and TIT each 8 weeks during all maintenance. *Pulses* with one single dose of VCR 1.5 mg/m^2^ and DEXA 4 mg/m^2^/day × 7 days were done each 8 weeks only during the first year of the maintenance treatment, for the LR Group of patients. Prophylactic CNS radiation was not performed in any LR.

###### 

**Therapy for very low-risk and low-risk ALL patients on GBTLI ALL-93 protocol**.

  Phase                                                                                       Length                                 
  ------------------------------------------------------------------------------------------- ----------------- -- -- -- -- -- -- -- --
  Induction, first phase                                                                      4 weeks                                
   Dexametasone 6 mg/m^2^/d orally × 28 days                                                                                         
   Vincristin 1.5 mg/m^2^/dose IV (maximum 2 mg); days 1, 8, 15, and 22                                                              
   Daunomycin 25 mg/m^2^/dose IV (1 h inf.); days 1, 8, 15, and 22                                                                   
   TIT[^a^](#tfn1){ref-type="table-fn"} at days 1 and 29                                                                             
  Induction, second phase                                                                     2 weeks                                
   Each 2 days, start day 29                                                                                                         
   [l]{.smallcaps}-Asparaginase 10,000 IU/m^2^/dose IM (1 h inf.) × 8 doses                                                          
   Cytarabine 75 mg/m^2^/d SC × 4 doses weekly; days 29--32 and 40--43                                                               
   TIT[^a^](#tfn1){ref-type="table-fn"} at day 43                                                                                    
  Intensification                                                                             6 weeks                                
   Each 2 weeks                                                                                                                      
   Methotrexate 2 g/m^2^ IV (24 h inf.) with                                                                                         
   LCV rescue 15 mg/m^2^/dose at hours 36, 42, 48, and 54                                                                            
   6-Mercaptopurine 50 mg/m^2^/d orally × 6 weeks                                                                                    
   TIT[^a^](#tfn1){ref-type="table-fn"} each 2 weeks after systemic MTX infusion (×4)                                                
  Reinduction, first phase                                                                    4 weeks                                
   Dexametasone 6 mg/m^2^/d orally × 21 days                                                                                         
   Vincristin 1.5 mg/m^2^/dose IV (maximum 2 mg); days 106, 113, 120, and 127                                                        
   [l]{.smallcaps}-Asparaginase 10,000 IU/m^2^/dose IM × 4 doses; days 106,109,113, and 116                                          
   TIT[^a^](#tfn1){ref-type="table-fn"} at day 106 and 126                                                                           
  Reinduction, second phase                                                                   2 weeks                                
   6-Mercaptopurine 50 mg/m^2^/d orally × 14 days                                                                                    
   Cytarabine 75 mg/m^2^/d SC × 4 doses weekly; days 134--137 and 145--148                                                           
   TIT[^a^](#tfn1){ref-type="table-fn"} at days 134, 141, and 148                                                                    
  Maintenance therapy randomization                                                           18 or 24 months                        
   GROUP 1 and GROUP 2                                                                                                               
   6-MP 50 mg/m^2^/d orally                                                                                                          
   MTX 25 mg/m^2^/dose IM weekly                                                                                                     
   TIT each 8 weeks                                                                                                                  
   For low-risk group, pulses every 8 wk                                                                                             
   DEXA 4 mg/m^2^ every other day × 3                                                                                                
   VCR 1.5 mg/m^2^ IV (maximum 2 mg) at day 1                                                                                        

*^a^Dose according to age*.

*GBTLI, Brazilian Childhood Cooperative Group for ALL Treatment; ALL, acute lymphoblastic leukemia; TIT, triple intrathecal chemotherapy (methotrexate, cytarabine, and dexamethasone); IV, intravenous; IM, intramuscular; SC, subcutaneous; Inf., infusion; 6MP, 6-mercaptopurine; MTX, methotrexate; VCR, vincristine; LCV, leucovorin; d, day; h, hour; w/, with; wk, week*.

###### 

**Therapy for high risk ALL patients on GBTLI ALL-93 protocol**.

  Phase                                                                                             Length                                                         
  ------------------------------------------------------------------------------------------------- ----------------- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
  Induction, first phase                                                                            4 weeks                                                        
   Dexametasone 6 mg/m^2^/d orally × 28 days                                                                                                                       
   Vincristin 1.5 mg/m^2^/dose IV (maximum 2 mg); days 1, 8, 15, and 22                                                                                            
   Daunomycin 25 mg/m^2^/dose IV (1 h inf.); days 1, 8, 15, and 22                                                                                                 
   [l]{.smallcaps}-Asparaginase 10,000 IU/m^2^/dose IM (1 h inf.) × 8 doses; days 15--22                                                                           
   TIT[^a^](#tfn2){ref-type="table-fn"} at days 1, 15, and 29                                                                                                      
  Induction, second phase                                                                           2 weeks                                                        
   Cytarabine 750 mg/m^2^/d IV (3 h inf.) each 12 h × 6 doses; days 36--38                                                                                         
   [l]{.smallcaps}-Asparaginase rescue 6,000 IU/m^2^/dose IM × 6 doses at hour 6                                                                                   
   TIT[^a^](#tfn2){ref-type="table-fn"} at day 43                                                                                                                  
  Intensification                                                                                    6 weeks                                                       
   Each 2 weeks                                                                                                                                                    
   Methotrexate 2 g/m^2^ IV (24 h inf.) with                                                                                                                       
   LCV rescue 15 mg/m^2^/dose at hours 36, 42, 48, and 54                                                                                                          
   6-Mercaptopurine 50 mg/m^2^/d orally × 6 weeks                                                                                                                  
   TIT[^a^](#tfn2){ref-type="table-fn"} each 2 week after systemic MTX infusion (×4)                                                                               
  Reinduction, first phase                                                                           4 weeks                                                       
   Dexametasone 6 mg/m^2^/d orally × 21 days                                                                                                                       
   Vincristin 1.5 mg/m^2^/dose IV weekly (maximum 2 mg); days 106, 113, 120, and 127                                                                               
   [l]{.smallcaps}-Asparaginase 10,000 IU/m^2^/dose IM × 4 doses; days 106,109,113, and 116                                                                        
   TIT[^a^](#tfn2){ref-type="table-fn"} at day 106 and 126                                                                                                         
  Reinduction, second phase                                                                         2 weeks                                                        
   6-Mercaptopurine 50 mg/m^2^/d orally × 14 days                                                                                                                  
   Cytarabine 75 mg/m^2^/d SC × 4 doses weekly; days 134--137 and 145--148                                                                                         
   TIT[^a^](#tfn2){ref-type="table-fn"} at days 134, 141, and 148                                                                                                  
   CNS RT[^a^](#tfn2){ref-type="table-fn"}                                                                                                                         
  Maintenance therapy, first phase (weeks 23--77)                                                   18 or 24 months                                                
   Block A (6 blocks) weeks 23, 32, 41, 50, 59, and 68                                                                                                             
    Cytarabine 750 mg/m^2^/d IV (3 h inf.) each 12 h × 6 doses; days 36--38                                                                                        
    [l]{.smallcaps}-Asparaginase rescue 6,000 IU/m^2^/dose IM × 6 doses at hour 6                                                                                  
   Block B                                                                                                                                                         
    DEXA 3 mg/m^2^/d orally × 21 days                                                                                                                              
    VCR 1 mg/m^2^ IV (maximum 2 mg) at days 1,8, and 15                                                                                                            
   Block C                                                                                                                                                         
    6-MP 75 mg/m^2^/d orally × 21 days                                                                                                                             
    MTX 40 mg/m^2^/dose IM; days 1, 8, and 15                                                                                                                      
  Maintenance therapy, second phase                                                                                                                                
   Pulses every 8 wk (start week 77 until the week 103, for group 1 or the week 130, for group 2)                                                                  
   DEXA 4 mg/m^2^/d orally × 7 days                                                                                                                                
   VCR 1.5 mg/m^2^ IV (maximum 2 mg) at day 1                                                                                                                      
   6-MP 50 mg/m^2^/d orally                                                                                                                                        
   MTX 25 mg/m^2^/dose IM weekly                                                                                                                                   
   TIT[^a^](#tfn2){ref-type="table-fn"} each 8 weeks, except for CNS radiated patients                                                                             

*^a^Dose according to age*.

*GBTLI, Brazilian Childhood Cooperative Group for ALL Treatment; ALL, acute lymphoblastic leukemia; TIT, triple intrathecal chemotherapy (methotrexate, cytarabine, dexamethasone); IV, intravenous; IM, intramuscular; SC, subcutaneous; Inf., infusion; 6MP, 6-mercaptopurine; MTX, methotrexate; VCR, vincristine; LCV, leucovorin; d, day; h, hour; w/, with; wk, week; CNS, central nervous system; RT, radiation therapy*.

Patients of the HR Group received the *induction therapy*, as for the low-risk patients, with additional high-dose Ara-C 750 mg/m^2^ IV 3 h infusion each 12 h × 6 doses beginning at day 36, and [l]{.smallcaps}-ASP rescue at a dose of 6,000 U/m^2^ IM. *Intensification phase* was the same as for the low-risk group. *Reinduction phase* as for the low-risk group, except for the prophylactic CNS irradiation with 18 Gy (CNS-1 and CNS-2 patients) or 24Gy (CNS-3 patients). *Maintenance therapy* with rotating blocks A, B, and C from week 23 till week 77 (Block A = Ara-C 750 mg/m^2^ IV 3 h infusion each 12 h × 6 doses and [l]{.smallcaps}-ASP 6,000 U IM/m^2^ 6 h after the last Ara-C dose; Block B = DEXA 3 mg/m^2^/day × 21 days and VCR 1.0 mg/m^2^/week × 3, and Block C = 6-MP 75 mg/m^2^/day × 3 weeks and MTX 40 mg/m^2^/week IM × 3). After week 77, patients received daily 6-MP 50 mg/m^2^ continuously and MTX 25 mg/m^2^/week IM and pulses of one single dose of VCR 1.5 mg/m^2^ and DEXA 4 mg/m^2^/day × 7 were prescribed each 8 weeks, either until week 103 (group 1) or week 130 (group 2). Full dose chemotherapy was recommended with WBC ≥ 2,000/mm^3^, total phagocytes ≥500/mm^3^, and platelets counts ≥100,000/mm^3^.

It is important to emphasize that the overall treatment duration refers to the actual therapy received by the patient. Periods without programed chemotherapy were compensated.

Statistical Analysis {#S3}
====================

Kaplan--Meier curves were used to illustrate children's overall or EFS, and log rank tests to compare the curves for distinct groups of children. Overall survival (OS) was defined as the time period from diagnosis to death. EFS was defined as the time from diagnosis of ALL until the date of either induction failure, relapse, death in remission from any cause, the development of a second cancer, or until the date of last contact for all event-free survivors. Thirty-four patients (4.0%) were lost to follow-up: 12 children who were lost of follow-up after cessation of therapy (5.3 years of mean EFS), 9 during the maintenance phase (mean EFS 0.3 years), and 2 without reaching remission (EFS = 0). Maintenance EFS (M-EFS) was defined as the time from the beginning of the maintenance phase to relapse or death. Comparison between groups was done based on the intention-to-treat. The significance level was set at *p* ≤ 0.05. Statistical analyses were performed with the SPSS 20.0 software (SPSS Inc., Chicago, IL, USA) on the basis of data obtained up to June, 2016.

Results {#S4}
=======

From October 1993 to September 1999, 867 consecutive patients from 25 Brazilian Institutions entered the study. Only 14 patients (1.6%) were excluded from the analysis for the following reasons: AML diagnosis (7 patients) and previous corticosteroid use (7 patients). In total, 853 patients were analyzed, being 406 of them classified as HR (48%). Clinical and laboratorial data are listed in Table [3](#T3){ref-type="table"}. After induction therapy, 817 children (96%) achieved clinical complete remission (CCR). Thirty-six patients (4%) had induction failure. Twenty-eight children died during this initial phase (3.4%), mainly due to infections. Thirty-four patients (4.0%) were lost to follow-up. The mean time of follow-up for children without an event was 12.8 years (interquartile range: 5.7 years). Any event was registered in 285 patients. For these children, the median time to an event was 1.9 years (interquartile range 2.6 years). Clinical outcomes are summarized in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. Over 15 years of follow-up, 2 patients both from group 2 presented a second malignancy (Hodgkin's disease and thyroid carcinoma) after 8.3 and 11 years of therapy, respectively.

###### 

**Clinical and laboratorial data of 853 patients with ALL treated with GBTLI ALL-93 protocol**.

                                            No. of cases   \%
  ----------------------------------------- -------------- ------
  Registered patients                       867            100
  Excluded patients                         14             1.6
   AML diagnosis                            7              
   Previous corticosteroids use             7              
  Total of analyzed patients                853            98.4
  White                                     627            73.5
  Non-white                                 226            26.5
  Age (in years)                                           
   \<1                                      23             2.7
   ≥1 to \<10                               636            74.6
   ≥10                                      194            22.7
  Gender                                                   
   Male                                     437            51.2
   Female                                   416            48.7
  WBC (/mm^3^)                                             
   \<10,000                                 378            44.3
   ≥10,000 to \<50,000                      252            29.5
   ≥50,000 to \<100,000                     94             11.0
   ≥100,000                                 129            15.1
  Risk group                                               
   Very low risk                            154            18.0
   Low risk                                 293            34.3
   High risk                                406            47.6
  CNS involvement at Dx                     23             2.7
  Testis involvement at Dx                  8              0.9
  Immunophenotype test                                     
   T-ALL                                    76             12.8
   B-ALL                                    517            87.2
   Not performed                            197            
   Not referred                             63             
  Calla antigen (CD10) positive             475            85.3
  Calla antigen (CD10) negative             82             14.7
  Not performed                             296            
  Cytogenetic                                              
   Exam performed                           57             6.7
   Normal                                   27             47.4
   Hyperdiploidy                            11             19.3
   Hypodiploid                              3              5.3
   Not attained metaphases                  16             28.0
  Not performed                             796            93.3
  Molecular biology                                        
   Exam performed                           91             10.6
   Chromos without abnormalities analyzed   66             72.5
   Chromos abnormalities                    25             37.8
    *t* (12; 21)                            15             
    *t* (1; 19)                             5              
    *t* (4; 11)                             1              
    *t* (9; 22)                             4              
    Not performed                           762            89.3

###### 

**Clinical outcomes of 853 ALL patients treated according to GBTLI ALL-93 protocol**.

                                                 No. of cases   \%
  ---------------------------------------------- -------------- ------
  Total number of analyzed patients              853            100
  Attained remission at the end of induction     817            96
  Induction failure (include induction deaths)   36             4
  In CCR                                         590            69.1
  Blast D8 (/mm^3^)                                             
   \<1,000                                       751            88.0
   ≥1,000                                        39             4.6
   Not performed                                 63             
  WBC D8 (/mm^3^)                                               
   \<10,000                                      766            89.8
   ≥10,000 and \<50,000                          23             2.7
   ≥50,000 and \<100,000                         3              0.3
   ≥100,000                                      0              
   Not performed                                 61             
  Site of relapses                                              
   BM                                            138            16.1
   CNS                                           12             1.4
   Others                                        6              0.7
   Combined                                      15             1.7
  Death                                                         
   In induction                                  28             3.3
   In remission                                  56             6.7
   After relapse                                 154            18.0
   Not remission                                 6              0.7
   After BMT                                     1              0.1
  Lost of follow-up                              34             4.0
  Mean of follow-up                              9.1 years      

###### 

**Treatment results according to clinical and laboratorial data of 853 ALL patients treated with the GBTLI ALL-93 protocol**.

                                                                 EFS at 15 years   95% confidence interval   *p* Value
  -------------------------------------------------------- ----- ----------------- ------------------------- -----------
  Sex                                                                                                        
   Male                                                    437   0.662             0.617--0.707              0.98
   Female                                                  416   0.659             0.612--0.706              
  Age                                                                                                        
   \<1 year                                                23    0.304             0.116--0.492              \<0.00001
   ≥1 to \<10 years                                        636   0.706             0.670--0.743              
   ≥10 years                                               194   0.554             0.483--0.624              
  WBC (×10^9^/L)                                                                                             
   \<10 × 10^9^/L                                          378   0.721             0.674--0.768              \<0.00001
   10−50 × 10^9^/L                                         252   0.676             0.617--0.734              
   50−100 × 10^9^/L                                        94    0.563             0.463--0.664              
   ≥100 × 10^9^/L                                          129   0.527             0.440--0.612              
  WBC (×10^9^/L)                                                                                             
   \<50 × 10^9^/L                                          630   0.703             0.666--0.740              \<0.00001
   ≥50 × 10^9^/L                                           223   0.542             0.477--0.607              
  Immunophenotype^^a^^[](#tfn3){ref-type="table-fn"}                                                         
   Pre-B CD10 positive                                     473   0.731             0.690--0.772              \<0.00001
   Pre-B CD10 negative                                     44    0.475             0.327--0.623              
   T-cell                                                  76    0.460             0.348--0.572              
  NCI risk groups                                                                                            
   Standard risk                                           447   0.773             0.732--0.814              \<0.00001
   High risk                                               406   0.538             0.489--0.587              
  GBTLI risk group                                                                                           
   Very low risk                                           154   0.787             0.721--0.853              \<0.00001
   Low risk                                                293   0.765             0.715--0.816              
   High risk                                               406   0.538             0.489--0.587              
  CNS status^[^a^](#tfn3){ref-type="table-fn"}^                                                              
   Positive                                                23    0.566             0.364--0.768              0.17
   Negative                                                830   0.668             0.635--0.701              
  Testicular involvement                                                                                     
   Yes                                                     8     0.750             0.450--1.000              0.75
   No                                                      429   0.660             0.615--0.705              
  Mediastinal involvement                                                                                    
   Yes                                                     54    0.572             0.439--0.705              0.08
   No                                                      799   0.667             0.634--0.700              
  D8 peripheral WBC^[^a^](#tfn3){ref-type="table-fn"}^                                                       
   \<5 × 10^9^/L                                           703   0.693             0.658--0.728              \<0.00001
   ≥5 × 10^9^/L                                            89    0.493             0.389--0.597              
  D8 peripheral blast^^a^^[](#tfn3){ref-type="table-fn"}                                                     
   Positive                                                182   0.531             0.457--0.605              \<0.00001
   Negative                                                608   0.713             0.676--0.750              

*^a^There are missing values for some children*.

The long-term 15-year OS was 70.0 ± 1.6% (Figure [1](#F1){ref-type="fig"}A). The overall EFS rate was 66.1 ± 1.7% (Figure [1](#F1){ref-type="fig"}B). No difference was detected according to the two maintenance regimens: group 1 (18-month duration) with pEFS~15y~ = 65.8 ± 2.3% and group 2 (24-month duration) with pEFS~15y~ = 66.3 ± 2.3% (*p* = 0.79; Figure [1](#F1){ref-type="fig"}C). Furthermore, even after stratifying the analyses according to the risk groups, there were no statistically significant differences in the EFS of group 1 vs. group 2, either among the very low and low-risk patients (*p* = 0.33), or among high-risk patients (*p* = 0.62). The same observation holds true relatively to gender (*p* = 0.60 and *p* = 0.87 for males and females, respectively), to age group (\<1 year, ≥1 \< 10 years, and ≥10 years), and WBC at diagnosis (\< or ≥50,000/mm^3^). If only children who started the maintenance phase were considered (*n* = 760, 373 from 18-month group, and 387 from the 24-month group), excluding those who relapsed or died before it, the M-EFS was 74.3 ± 2.3% for group 1 and 74.0 ± 2.3% for group 2 (*p* = 0.99; Figure [1](#F1){ref-type="fig"}D).

![**Long-term survival of 853 ALL-children treated by GBTLI ALL-93 protocol: (A) overall survival, (B) event-free survival, (C) EFS according to maintenance regimen length, (D) M-EFS according to maintenance regimen length**.](fped-04-00110-g001){#F1}

The overall death in remission rate was 6.8% (56 patients). Importantly, of the 25 deaths that happened during the maintenance phase, 13 were from group 1 and 12 from group 2, all of them due to infections.

According to the protocol risk group, the pEFS~15yr~ was 78.7 ± 3.4% (VLR group, *n* = 154), 76.5 ± 2.6% (LR, *n* = 293), and 53.8 ± 2.5% (HR Group, *n* = 406) (Figure [2](#F2){ref-type="fig"}A, *p* \< 0.0001). According to age, children \<1-year-old (*n* = 23) had a pEFS~15yr~ of 30.4 ± 9.6%; those \>10-year-old (*n* = 194) had a pEFS~15y~ of 55.4 ± 3.6%, and those ≥1 and \<10 years of age (*n* = 636) had a pEFS~15yr~ of 70.65 ± 1.8% (Figure [2](#F2){ref-type="fig"}B, *p* \< 0.0001). Patients with initial WBC counts ≤10,000/mm^3^ (*n* = 378) had better pEFS~15yr~ rates as compared to those with ≥100,000/mm^3^ (*n* = 129): 72.1 ± 2.4 vs. 52.7 ± 4.4%, respectively (Figure [2](#F2){ref-type="fig"}C, *p* \< 0.0001).

![**Event-free survival of 853 ALL-children treated by GBTLI ALL-93 protocol: (A) according to the protocol risk factors, (B) according to age at diagnosis, (C) according to WBC count at diagnosis**.](fped-04-00110-g002){#F2}

Only 593 patients (69.5%) had immunophenotypic analysis performed at diagnosis: 12.8% were T-cell ALL (*n* = 76), 7.4% were pre-B CD10 negative (*n* = 44), and 79.8% pre-B CD10 positive (*n* = 473). The pEFS~15yr~ for these three groups were 46.0 ± 5.7%, 47.5 ± 7.6%, and 73.1 ± 2.1%, respectively (*p* \< 0.0001). Only 57 patients (6.7%) had cytogenetic and 91 patients (10.7%) had molecular biology studies performed.

Even though initial response to therapy was not used for further children's allocation into the risk groups, patients with peripheral WBC counts \<10,000/mm^3^ at day 8 (D8) (*n* = 766) had long-term EFS of 68.2 ± 1.7%, while for those with ≥10,000/mm^3^ (*n* = 26) the EFS was 34.6 ± 9.3% (*p* \< 0.0001) (Figure [3](#F3){ref-type="fig"}A). Similar results were observed in patients with D8 WBC \< 5,000/mm^3^ (*n* = 703) when compared to those with ≥5,000/mm^3^ (*n* = 89): EFS = 69.3 ± 1.8 vs. 49.3 ± 5.3%, respectively (*p* \< 0.0001). In addition, patients with any peripheral blasts at D8 (*n* = 182) had a worse prognosis than those with negative blasts (*n* = 608; *p* \< 0.0001). Combined analysis revealed that patients with D8 WBC ≥ 5,000/mm^3^ and any blasts at D8 had a significantly poorer pEFS~15yr~ than patients with D8 WBC \< 5,000/mm^3^ and no blast at D8 (*p* \< 0.0001) (Figure [3](#F3){ref-type="fig"}B).

![**Event-free survival of 853 ALL-children treated by GBTLI ALL-93 protocol related to initial induction therapy response (at D8): (A) according to peripheral WBC counts, (B) according to the presence of any blast and WBC counts**.](fped-04-00110-g003){#F3}

Discussion {#S5}
==========

The GBTLI started the first trial in 1980. Consecutive studies ALL-82 and ALL-85 contributed to significant improvement of the survival cure rates for the Brazilian children and adolescents up to 70 ± 4% of EFS ([@B11]). Results here presented for the GBTLI ALL-93 (EFS~15y~ = 66.1 ± 1.7%) are comparable to both our earlier results (GBTLI ALL-85) and those obtained in other prospective treatment protocols for childhood ALL conducted by international cooperative groups in HICs over a similar period of time (1981--2000): UKALLX1 (EFS~5yr~ = 63.1 ± 2.2%) ([@B12]), COALL-92 (EFS~5yr~ = 76.9 ± 1.9%) ([@B13]), DCLSG-ALL-8 (EFS~5yr~ = 73 ± 2%) ([@B14]), EORTC-CLG 58881 (EFS~5yr~ = 70.9 ± 1.1%) ([@B15]), NOPHO ALL92 (EFS~5yr~ = 77.6 ± 1.4%) ([@B16]), BFM-95 ALL (EFS~5y~ = 79.6%) ([@B17], [@B18]), and AIEOP-95 (EFS~5y~ = 75.9%) ([@B19]).

It is difficult to compare the GBTLI ALL-93 protocol results with other contemporary published reports from the literature, considering that those studies included different ages, clinical, and laboratorial (immunophenotyping, cytogenetic, and ploidy) criteria for the group risk definitions. At that time, only age, WBC, and clinical extra medullary involvement of the disease were defined as risk criteria in our studies. Brief reports of our results have already been presented ([@B20]). Additionally, it is known that racial, nutritional, and socioeconomic variables also influence the survival of pediatric patients with acute leukemia ([@B21]--[@B24]).

Survival for children and adolescents with ALL has improved over time due to more precise risk classification and refinement of post-induction therapy through serial clinical trials ([@B25]). As one induction intensification and one or two consolidation therapies have improved cure rates of this disease, the necessity of several years of maintenance therapy has been recently questioned ([@B5]). As already mentioned, a systematic review of several randomized studies on childhood ALL, indicates that longer maintenance therapy did not improve survival because the somewhat lower risk of relapse was counterweighed by a higher risk of death in remission ([@B10]). Furthermore, longer as well as higher 6MP/MTX doses have, in three recent studies, been associated with an increased risk of second malignancies ([@B6], [@B7], [@B26]). In the GBTLI ALL-93 study, two second malignancies were registered in children from group 2 (24-month maintenance).

The long-term clinical results of the GBTLI ALL-93 protocol showed that it was feasible to shorten to only 18 months, the maintenance therapy for ALL patients, in the Brazilian setting. It remains to be seen if the modern protocols that reached survival rates above 85% depend upon the duration of the maintenance therapy. The lower survival rate in our study was mainly due to induction mortality and death in remission, predominantly, because of infections. Also, it is important to emphasize that in order to "overcome" the lack of diagnostic tools, the post-induction therapy was much more aggressive for the high-risk patients of the study, mainly because the high-dose Ara-C (750 mg/m^2^ × 6 doses) starting on day 36, shortly after obtaining the remission. Twenty-three patients died before attaining the maintenance period, 17 of them belonging to the HR.

Whether these patients who died due to toxicity and/or infections would benefit from a longer maintenance, has yet to be addressed. However, the fact that the next GBTLI ALL-99 protocol has already adopted the shorter maintenance therapy (18-month duration) with reasonable survival rates ([@B27]) allows us to suggest that such reduction may generally be advantageous for the patients. In our experience, there is no clear benefit to prolong this phase, neither considering the gender nor the NCI risk criteria at diagnosis. The possibility to decrease in 6 months, the treatment duration, contributes to more days at school, less expenditure with transportation to the clinics, and probably better quality of life. However, there is evidence that shortening the maintenance therapy too much may be risky. A previous study that shortened the total protocol duration from 2 to 1.5 years, significantly reduced the EFS. When all chemotherapy was limited to 52 weeks from diagnosis, the pEFS~5y~ was as low as 60%, even for non-high-risk ALL patients ([@B28]).

Even though early response evaluation to induction therapy was not used for patient's stratification, D8 peripheral WBC counts were routinely recorded in the present study. Peripheral blast count reduction is well established by different investigators as a prognostic factor ([@B17], [@B29]). The GBTLI ALL-93 protocol proposed the simple WBC counts at D8 of treatment, as a predictor for therapy failure, based on previous data from our group showing that WBC counts were highly predictive of outcome ([@B19], [@B30]). The present study validated these earlier findings by showing that patients with either D8 peripheral WBC \> 5,000 leukocytes/mm^3^ or the presence of any blast in D8 peripheral blood had adverse prognosis. Persistence of circulating blasts in peripheral blood at D8 after multi-agent chemotherapy in individual ALL patients had been previously reported as a poor prognostic factor with a relative risk of 2.9 (*p* \< 0.0001) ([@B31]).

The rational of the study GBTLI ALL-93 was that shortening the maintenance therapy could increase survival both by reducing the immunosuppressive period and improving patient adherence. However, death in the maintenance phase was equally distributed between the two groups. Despite socioeconomic difficulties in Brazil at that time, only 4.0% of the patients were lost to follow-up. Lack of adherence to oral chemotherapy has been reported in children with ALL ([@B32], [@B33]), that was the reason to maintain, in this study, the MTX by IM route during all the maintenance therapy. Facilitators and barriers to adherence were not analyzed as part of the GBTLI ALL-93 study.

The GBTLI ALL-93 study offered a unique opportunity to address ALL treatment in the context of restricted access to modern technologies. Therapeutic strategies capable of overcoming these limitations in low- and middle-income countries remain an important topic to be investigated in the future, with controlled prospective studies performed in those parts of the world.

Unfortunately, recent national published data reveal a 5-year OS of only 47% for children with ALL living in different regions of Brazil. Those rates have not changed for a period of three decades (1996--2008) ([@B34]--[@B36]). Similarly, national published data from 1996 to 2008, covering different geographical regions of Brazil, reveal no changes in mortality rates due to leukemia in patients with \<20 years of age. Surprisingly, differences between the rich and poor geographic areas of the country are lower than 2% ([@B34]). It is noteworthy that the survival rates of children with ALL living in the Rio Grande do Sul State reached EFS~5y~ = 62.41 ± 2.43% when treated with the GBTLI ALL protocols, while patients not included in any study had EFS~5y~ = 49.47 ± 4.15% ([@B37]). Unfortunately, less than 1% of the estimated new ALL patients with \<18 years are registered in the GBTLI.

In 2015, there were 187 centers in Brazil registered at the Health Ministry for the care of children with cancer. Only 67 institutions were accredited for pediatric oncology care ([@B38]). How could children's mortality rates due to cancer be reduced in low- and middle- income countries? Probably by: (1) limiting the number of specialized centers to deliver pediatric cancer treatment, (2) reinforcing and promoting institutional participation in cooperative prospective protocols with an overarching and monitoring structure, and (3) establishing a national health policy for accreditation and governance of childhood cancer treatment centers ([@B3]).

Conclusion {#S6}
==========

Within the GBTLI ALL-93 protocol, the length of maintenance therapy could be safely abbreviated to 18 months, independently of the patient's gender and risk group defined by age, WBC counts, and clinical extramedullary ALL involvement at diagnosis. It was feasible to achieve in Brazil long-term OS rates of 70% for children with ALL, corroborating the value of national prospective cooperative studies. The possibility of decreasing the maintenance treatment by 6 months may contribute to overcome major financial and cultural obstacles, remaining as adverse situations in middle- and low-income countries.
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